Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Spark's Vision Loss Gene Therapy Raises US FDA Questions About Novel Endpoint

Executive Summary

Multi-luminance mobility testing was developed by firm to measure functional vision across a range of lighting levels in patients with RPE65 mutations; advisory committee also will consider minimum patient age and clinical stage of disease appropriate for subretinal injections with voretigene.


Related Content

Spark's Early Christmas Present: US FDA Approves Luxturna For Vision Loss
How To Build An Endpoint: Spark Designed Testing Maze To Study Rare Vision Loss
Spark's Gene Therapy Luxturna Sails Through US FDA Panel
Spark's Gene Therapy Is On The Cusp Of Approval; Now It Gets Interesting
Novartis CAR-T Therapy's Swift Approval Aided By REMS And New US FDA Review Model
Spark Therapeutics' Vision Loss Gene Therapy Gets FDA Panel Review
Novartis CAR-T Site Selection, Risk Management Are Model For Other Sponsors


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts